Mania following ketamine abuse

Lu, Yuanyuan; Lin, Chieh‐Hsin; Lane, Hsien‐Yuan

doi:10.2147/ndt.s97696

Cited by 4 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To reduce postoperative opioid use, ketamine was infused at 0.2 mg/kg/h over 4 days, and expansive affect, sleep-deprived energy enhancement, grandiosity, hypersexuality, and disinhibition occurred. The fifth case of reported ketamine-induced mania described a patient with Tourette syndrome and OCD who abused ketamine by inhaling (15). One case report describes a 17-year-old man with cerebral palsy experiencing hypomaniclike symptoms possibly connected to two ketamine administrations for sedation during dental procedures.…”

Section: Discussionmentioning

confidence: 99%

Affective Switch Associated With Oral, Low Dose Ketamine Treatment in a Patient With Treatment Resistant Bipolar I Depression. Case Report and Literature Review

et al. 2020

View full text Add to dashboard Cite

There is a growing evidence for the rapid and robust antidepressive effect of ketamine in unipolar and bipolar treatment resistant depression although evidence for the risk of affective switch is still limited. This case presents bipolar I disorder patient with treatment resistant depressive episode experiencing a switch to manic episode with mixed features shortly after receiving eight subanaesthetic doses of oral ketamine as an add-on treatment preceded by 2-day period of manic symptoms.

show abstract

Section: Discussionmentioning

confidence: 99%

Affective Switch Associated With Oral, Low Dose Ketamine Treatment in a Patient With Treatment Resistant Bipolar I Depression. Case Report and Literature Review

et al. 2020

View full text Add to dashboard Cite

show abstract

“…However, mania-like behaviors can also appear after a reduction in NMDAR-mediated antiactivity processes ( Garzón-Niño et al, 2017 ). In that sense, NMDAR antagonism causes transient mood elevation or euphoria and psychotomimetic effects similar to a manic-like syndrome ( Lu et al, 2016 ).…”

Section: Discussionmentioning

confidence: 99%

Sigma 1 Receptor Antagonists Inhibit Manic-Like Behaviors in Two Congenital Strains of Mice

Sánchez‐Blázquez

Cortés-Montero

Rodríguez-Muñoz

et al. 2018

International Journal of Neuropsychopharmacology

View full text Add to dashboard Cite

BackgroundSeveral currently available animal models reproduce select behavioral facets of human mania as well as the abnormal glutamatergic neurotransmission and dysregulation of glycogen synthase kinase 3β that accompanies this disease.MethodsIn this study, we addressed the therapeutic potential of ligands of sigma receptor type 1 (σ1R) in 2 putative models of mania: the “manic” Black Swiss outbred mice from Taconic farms (BStac) and mice with the 129 genetic background and histidine triad nucleotide-binding protein 1 (HINT1) deletion (HINT1-/- mice) that exhibit bipolar-like behaviors.ResultsThe activity of control mice, which do not exhibit manic-like behaviors in the forced swim test, was significantly enhanced by MK801, an inhibitor of glutamate N-methyl-D-aspartate receptor activity, an effect that was not or barely observed in manic-like mice. Typical mood stabilizers, such as glycogen synthase kinase 3β inhibitors, but not σ1R ligands, reduced the N-methyl-D-aspartate receptor-mediated behaviors in control mice. Notably, σ1R antagonists S1RA, PD144418, BD1047, and BD1063, but not σ1R agonists PRE084 and PPCC, attenuated the manic-like behaviors of BStac and HINT1-/- mice by increasing antiactivity behaviors. The antimanic effects of a single administration of σ1R antagonists persisted for at least 24 hours, and these drugs did not alter the behavior of the “bipolar” HINT1−/− mice during pro-depressive episodes.Conclusionsσ1R antagonists exhibit a selective normalizing effect on specific behavioral domains of mania without altering control (normal) or depressive-like behaviors.

show abstract

“…Amphetamine has been shown to trigger euphoria in healthy volunteers, mostly through increased dopamine levels in the anteroventral striatum. 31 In addition, Lu et al 32 indicated a possible relationship between manic symptoms and ketamine abuse in a case report. This relationship may be attributed to the increased dopamine level in the brain tissue brought about through dopamine release after chronic dosing with ketamine.…”

Section: Biological Backgroundmentioning

confidence: 99%

Noradrenaline plays a critical role in the switch to a manic episode and treatment of a depressive episode

Kurita¹

2016

NDT

View full text Add to dashboard Cite

Although antidepressants may increase the risk of switching to mania in bipolar disorder (BD), clinicians have been using antidepressants to treat patients with bipolar depression. Appropriate treatments for bipolar depression remain controversial. In BD, antidepressants comprise a double-edged sword in terms of their efficacy in treating depression and the increased risk of switching. This review presents an important table outlining the benefit in terms of depression improvement and the risk of switching in the clinical setting. It also proposes strategies based on the characteristics of antidepressants such as their pharmacology, specifically the equilibrium dissociation constant (KD) of the noradrenaline transporter. This table will be useful for clinicians while considering benefit and risk. Antidepressants augmenting noradrenaline may be effective in bipolar depression. However, it is easily presumed that such antidepressants may also have a risk of switching to mania. Therefore, antidepressants augmenting noradrenaline will be the recommended treatment in combination with an antimanic agent, or they may be used for short-term treatment and early discontinuation. The corresponding medical treatment guidelines probably need to be reevaluated and updated based on biological backgrounds. From previous studies, we understand that the stability of noradrenaline levels is important for BD amelioration, based on the pathophysiology of the disorder. It is hoped that researchers will reevaluate BD by conducting studies involving noradrenaline.

show abstract

Mania following ketamine abuse

Cited by 4 publications

References 14 publications

Affective Switch Associated With Oral, Low Dose Ketamine Treatment in a Patient With Treatment Resistant Bipolar I Depression. Case Report and Literature Review

Affective Switch Associated With Oral, Low Dose Ketamine Treatment in a Patient With Treatment Resistant Bipolar I Depression. Case Report and Literature Review

Sigma 1 Receptor Antagonists Inhibit Manic-Like Behaviors in Two Congenital Strains of Mice

Noradrenaline plays a critical role in the switch to a manic episode and treatment of a depressive episode

Contact Info

Product

Resources

About